Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Update

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 239,118 shares, a decrease of 74.5% from the June 30th total of 938,810 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily volume of 1,138,425 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On Jupiter Neurosciences

A number of large investors have recently modified their holdings of the business. Vestor Capital LLC increased its position in shares of Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after acquiring an additional 970,314 shares during the last quarter. Geode Capital Management LLC boosted its position in Jupiter Neurosciences by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after purchasing an additional 28,826 shares during the last quarter. Yorkville Advisors Global LP bought a new position in Jupiter Neurosciences in the fourth quarter valued at approximately $135,000. Finally, Allen Capital Group LLC bought a new position in Jupiter Neurosciences in the fourth quarter valued at approximately $31,000.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Jupiter Neurosciences Price Performance

NASDAQ:JUNS traded down $0.03 during trading hours on Friday, reaching $0.12. 6,810,308 shares of the stock were exchanged, compared to its average volume of 21,126,814. The stock has a market cap of $4.39 million, a PE ratio of -0.45 and a beta of 1.73. Jupiter Neurosciences has a twelve month low of $0.11 and a twelve month high of $1.84. The firm has a 50 day moving average of $0.22 and a 200 day moving average of $0.43.

Jupiter Neurosciences (NASDAQ:JUNS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.23 million.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.